目的分析KCNQ1及SLC30A8基因多态性与2型糖尿病(T2DM)患者的相关性。方法选取2015年9月~2017年9月间在本院确诊并接受治疗的T2DM患者100例作为观察组,选取同期在本院进行体检健康者100例作为对照组,收集两组对象早晨空腹静脉血5 m L,全...目的分析KCNQ1及SLC30A8基因多态性与2型糖尿病(T2DM)患者的相关性。方法选取2015年9月~2017年9月间在本院确诊并接受治疗的T2DM患者100例作为观察组,选取同期在本院进行体检健康者100例作为对照组,收集两组对象早晨空腹静脉血5 m L,全自动生化分析仪检测糖化血红蛋白、空腹血糖水平、胰岛素和血脂的水平,基因型检测使用单碱基延伸法,分析不同基因位点和T2DM相关性状况。结果 SLC30A8基因对照组TT、CT及CC基因型的频率依次为16%、52%及32%,观察组依次为13%、49%、38%,差异无统计学意义(χ~2=1.290,P>0.05);对照组T、C等位的基因频率依次为61%、39%,观察组依次为73%、27%,差异有统计学意义(95%CI=0.795~1.684,OR=1.205,χ~2=11.553,P<0.05)。观察组TT基因型血清FINS及HOMA-B高于CT基因型和CC基因型,观察组TT基因型血清TC、TG和FPG低于CT基因型和CC基因型,差异均有统计学意义(P<0.05);KCNQ1基因对照组TT、CT及CC基因型的频率依次为27%、41%及32%,观察组依次为24%、45%、31%,差异无统计学意义(χ~2=2.006,P>0.05);对照组T、C等位的基因频率依次为53%、47%,观察组依次为64%、36%,差异有统计学意义(95%CI=0.863-2.104,OR=1.171,χ~2=12.995,P<0.05),CC基因型血清TC、TG、FPG及Hb A1c低于CT、TT基因型,血清FINS高于CT、TT基因型,差异均有统计学意义(P<0.05)。结论 SLC30A8基因多态性rs13266634位点和KCNQ1基因多态性rs2237892位点和T2DM发病及血管并发症有一定相关性。展开更多
Objective To investigate a potential relationship between Solute carrier family 30 （zinc transporter） member 8 （SLC3OAS） rs13266634 variant and efficacy of rosiglitazone or repaglinide in treating newly diagnosed ...Objective To investigate a potential relationship between Solute carrier family 30 （zinc transporter） member 8 （SLC3OAS） rs13266634 variant and efficacy of rosiglitazone or repaglinide in treating newly diagnosed Chinese type 2 diabetes patients. Methods A total of 209 diabetic patients without any antihyperglycemic history were recruited and treated with repaglinide or rosiglitazone randomly for 48 weeks （104 and 105 patients, respectively）. Anthropometric measurements and clinical laboratory tests were carried out before and after the treatment. An non-synonymous variant rs13266634 was genotyped by matrix-assisted laser desorption ionization-time of flight mass spectroscopy. Results Ninety-one patients in repaglinide group and ninety-three patients in rosiglitazone group completed the study. 6 value of homeostasis model assessment of beta cell function （HOMA-B） and 6 value of fasting proinsulin levels were statistically significant between three genotype groups （P=0.0149 and 0.0246, respectively） after rosiglitazone treatment. However, no genotype association was observed in the repaglinide or rosiglitazone group with other parameters. Conclusion The SLC3OA8 variant was associated with the efficacy of insulin sensitizer monotherapy on insulin secretion in patients with newly diagnosed type 2 diabetes mellitus in Shanghai, China.展开更多
基金funded by National 863 Program (2006AA02A409)major program of Shanghai Municipality for Basic Research (08dj1400601)"Chen Guang" Project (09CG07)
文摘Objective To investigate a potential relationship between Solute carrier family 30 （zinc transporter） member 8 （SLC3OAS） rs13266634 variant and efficacy of rosiglitazone or repaglinide in treating newly diagnosed Chinese type 2 diabetes patients. Methods A total of 209 diabetic patients without any antihyperglycemic history were recruited and treated with repaglinide or rosiglitazone randomly for 48 weeks （104 and 105 patients, respectively）. Anthropometric measurements and clinical laboratory tests were carried out before and after the treatment. An non-synonymous variant rs13266634 was genotyped by matrix-assisted laser desorption ionization-time of flight mass spectroscopy. Results Ninety-one patients in repaglinide group and ninety-three patients in rosiglitazone group completed the study. 6 value of homeostasis model assessment of beta cell function （HOMA-B） and 6 value of fasting proinsulin levels were statistically significant between three genotype groups （P=0.0149 and 0.0246, respectively） after rosiglitazone treatment. However, no genotype association was observed in the repaglinide or rosiglitazone group with other parameters. Conclusion The SLC3OA8 variant was associated with the efficacy of insulin sensitizer monotherapy on insulin secretion in patients with newly diagnosed type 2 diabetes mellitus in Shanghai, China.
